Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 31,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 27, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

NCT00578903
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Cytoxan, Campath, Total Body Irradiation (TBI), FK-506, Methotrexate, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

NCT01486927
View directory record Official record
Conditions
Hemophilia A
Interventions
rVIII-SingleChain, Octocog alfa
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 27, 2026, 4:20 PM EDT
Recruiting Phase 1 Interventional

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

NCT04097561
View directory record Official record
Conditions
Idiopathic CD4 Lymphopenia
Interventions
Belimumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Galcanezumab for Vestibular Migraine

NCT04417361
View directory record Official record
Conditions
Vestibular Migraine
Interventions
Galcanezumab Prefilled Syringe, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

NCT01483742
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CB-280, Placebos
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Pharmacokinetics and Safety of Testosterone

NCT01370369
View directory record Official record
Conditions
Testicular Hypogonadism
Interventions
Testosterone gel (FE 99903)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
214
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 154 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

NCT00148941
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
4,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
24
States / cities
Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 27, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

NCT06210854
View directory record Official record
Conditions
HPV Infection
Interventions
pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses)
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

NCT00540605
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 27, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

NCT05462496
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

NCT03730662
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
74
States / cities
Anaheim, California • Covina, California • Greenbrae, California + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 27, 2026, 4:20 PM EDT
Enrolling by invitation Phase 4 Interventional

Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries

NCT07393503
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Methylprednisolone 4Mg Tab, Acetaminophen 500Mg Tab, Ibuprofen 200Mg Oral Tablet
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT00554827
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Vitamin B12, Folic Acid, Pralatrexate
Dietary Supplement · Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 27, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional

Local Ablative Strategies After Endovascular Radioembolization

NCT02611661
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
PET/MRI, Percutaneous ablation, Stereotactic body radiotherapy
Device · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 27, 2026, 4:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042
View directory record Official record
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 27, 2026, 4:20 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants

NCT07879170
View directory record Official record
Conditions
Healthy Participants
Interventions
EPX-100, EPX-100-Matching Placebo, Moxifloxacin, Moxifloxacin-Matching Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 4 Interventional

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, glyburide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 27, 2026, 4:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Diagnostic for Detection of COVID-19 Infection

NCT04742569
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
ClinOne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenwood Village, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 27, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

NCT02934269
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, CC-90006
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 27, 2026, 4:20 PM EDT
Active, not recruiting Phase 1 Interventional Results available

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

NCT03774654
View directory record Official record
Conditions
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
Interventions
CD19.CAR-aNKT cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

NCT04267120
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Research blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Palo Alto, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 27, 2026, 4:20 PM EDT